Resource Library

The Biomedical Prevention Implementation Collaborative (BioPIC)

The pipeline for HIV prevention products holds the potential to curb HIV incidence. But we know from previous products that translating trial efficacy to population impact is challenging without coordinated effort. The Biomedical Prevention Implementation Collaborative is pioneering an innovative, integrated and adaptable approach to product introduction, with a focus on injectable cabotegravir (CAB) for…

Coordinating Implementation Science for CAB for PrEP: Bridging from the HPTN 083 and 084 Open Label Extensions to Implementation

This document summarises key takeaways from the BioPIC Think Tank on early insights from the HIV Prevention Trials Network (HPTN) 083 and 084 studies’ Open Label Extensions, looking at effectiveness of cabotegravir for PrEP as HIV prevention.

Research

Coordinating Implementation Science for CAB for PrEP: Inclusion of Key Populations

This document summarises key takeaways from the BioPIC Think Tank focused on strategies to include trans and gender diverse people, gay and bisexual men who have sex with men, sex workers, and people who use and inject drugs in implementation science projects as well as the rollout and scale-up of cabotegravir for PrEP.

Research

Coordinating Implementation Science for CAB for PrEP: Linking Modellers with the Latest Implementation Science Evidence, September 2023

This document summarises key takeaways from a September 2023 BioPIC Think Tank to align modellers and implementation science researchers on data and evidence needs to address cabotegravir for PrEP evidence gaps.

Research

Coordinating Implementation Science: Taking Stock of PrEP Evidence

This document summarises key takeaways from the BioPIC Think Tank held in March 2024 to review existing PrEP evidence and evidence gaps to date.

Research

Coordinating Implementation Science for CAB for PrEP: Linking Modellers with the Latest Implementation Science Evidence, March 2024

This document summarises key takeaways from a March 2024 BioPIC Think Tank to ensure modellers and implementation science researchers remain aligned on the latest cabotegravir for PrEP data and evidence.

Research

Modelling Impact of Injectable Cabotegravir for PrEP on Drug Resistance

An important consideration in the scale-up of injectable cabotegravir (CAB) for PrEP is the potential for development of Integrase Strand Transfer Inhibitor (INSTI) resistance. To help stakeholders understand this issue further, Professor Andrew Phillips from University College London shared the results of an exercise modelling the impact of the introduction of CAB for PrEP on…

Financing & Costing, Testing

Product Introduction/Implementation Project Planning for Next-Generation PrEP

Early data from clinical trials has indicated that Cabotegravir (CAB) for PrEP is safe and effective. With an accelerated timeline for introduction of CAB for PrEP, AVAC and WHO convened a think tank to strategize about demonstration projects and other planning for product introduction.

HIV Testing and Injectable Cabotegravir (CAB for PrEP) Introduction: What are the implications for HIV prevention scale-up and the HIV response?

One challenge which has emerged with the introduction of CAB for PrEP is the risk of Integrase Strand Transfer Inhibitor (INSTI) resistance amongst people who acquire HIV while taking CAB as prescribed. To address emerging evidence around testing algorithms and INSTI resistance in CAB users, AVAC and WHO convened a think tank with program implementers,…

Testing

Coordinating Implementation Science for CAB for PrEP

As implementation studies for injectable cabotegravir (CAB) for PrEP are being considered and as programs shift towards choice-based models for HIV prevention, there is a chance to correct for missed opportunities with oral PrEP rollout, understand client preferences and patterns of use, and ensure more effective coordination across geographies, populations, and projects. To facilitate this…

Research

Implementation Science Questions for CAB for PrEP

This document outlines the key evidence gaps around cabotegravir (CAB) for PrEP that should be addressed when designing implementation research.

Research